• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Interleukin-6 is a highly prognostic biomarker for POEMS syndrome

by MM360 Staff | Jul 12, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Targeting proteostasis in multiple myeloma through inhibition of LTK

by MM360 Staff | Jul 9, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

IsaKRD Induction Achieves 95% Response Rate in Multiple Myeloma

by MM360 Staff | Jul 9, 2025 | Myeloma News

Source: Pharmacy Times articles New data reveals isatuximab-based therapy achieves high MRD-negativity rates in newly diagnosed multiple myeloma. Read More

EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

by MM360 Staff | Jul 7, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Patient-reported physical function has ‘real clinical value’ for treating multiple myeloma

by Josh Friedman | Jul 7, 2025 | Uncategorized

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis of individuals diagnosed with multiple myeloma showed that those who reported having “low” physical function, such as struggling to do...
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • (no title)
  • Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
  • Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression
  • (no title)
  • (no title)
  • Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT